The insider selling is routine and immaterial in size. Monitor for any upcoming clinical or regulatory catalysts (CYTK is a biotech) that could drive the stock, but this cluster provides no actionable edge.
CYTK drugs
CYTK drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 8 $84.88entry
- T+1 · 4mo ago +1.40%α +0.56% · $86.07
- T+5 · 4mo ago −2.66%α −3.92% · $82.62
- T+20 · 3mo ago −7.10%α −10.38% · $78.85
- T+60 · 7w ago −22.69%α −25.18% · $65.62
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Four CYTK insiders (CEO, CFO, CCO, EVP R&D) sold a total of $2.32M in shares over a one-week window, but this represents only ~0.02% of the company's $10.6B market cap. The sales are trivial in proportion to company size and include a routine cashless exercise by the EVP R&D. No material signal for the stock.
Key Financial Metrics
Key Facts
- Total insider sales of $2.32M over 7 days (4 transactions)
- Sales represent ~0.02% of CYTK's $10.6B market cap
- CEO Robert Blum sold $637K, CCO Andrew Callos sold $1.29M, CFO Sung Lee sold $98K, EVP R&D Fady Malik sold $303K (including derivative exercise)
- All sales are open-market or cashless exercises; no pattern suggests material non-public information
Financial Impact
Insider sales of $2.32M, negligible relative to $10.6B market cap
Risk Factors
- Insider sales could increase if the stock continues to appreciate, but current levels are trivial
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-CYTK-1783490503419 |
Track record
46 reports on CYTK
7 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +8.59% at T+20 after the Sep 15, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $53.76 Now $56.13 +4.41% settles Dec 15
- Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $56.13 Now $56.13 +0.00% settles Dec 14
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $56.18 Now $56.13 −0.09% settles Dec 9
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $56.18 Now $56.13 −0.09% settles Dec 9
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $55.14 Now $56.13 +1.80% settles Dec 8
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $55.14 Now $56.13 +1.80% settles Dec 8
- Nov 4, 202612d ago 8-K Bullish 6/10 No price data
- Nov 4, 202612d ago Press Release Neutral 5/10 Entry $55.55 Now $56.13 +1.04% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $63.60 Now $56.13 −11.75% settles Dec 3
- Nov 2, 202614d ago Press Release Neutral 3/10 Entry $62.03 Now $56.13 −9.51% settles Dec 1
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers